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Abstract 
A serum-free supernatant from an epidermal carcinoma cell line has previously been shown to contain mitogenic activity for human 
tumor infiltrating lymphocytes in culture [1]. From this conditioned medium we have now purified to homogeneity, asdetermined by 
SDS-PAGE analysis, a ca. 45 kDa protein which stimulates [3H]thymidine incorporation i to the DNA of these human T-lymphocytes. 
Amino acid composition data and immunoreactivity of the purified protein as well as sequence analyses of 7 tryptic fragments obtained 
therefrom suggest a strong similarity with human monocyte/neutrophil elastase inhibitor, which is a member of the serine protease 
inhibitor (serpin) superfamily. We have previously identified and purified from the same conditioned medium a 36 kDa protein with 
myeloid immunomodulatory .,activity [2]. Taken together, these two reports support he role of tumor-derived soluble factors in tumor 
immunosurveillance. 
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1. Introduction 
The idea that the tumor environment contains immuno- 
cytes which, if properly ~unplified and/or  activated, are 
potential antitumor agents has served as the basis for 
various immunotherapeutic clinical trials [3-5]. Although 
many studies have been aimed toward understanding the 
initiation of an immune response as being a result of direct 
tumor cell-immunocyte contact, the possibility of tumor 
Abbreviations: TIL, tumor infiltrating lymphocyte; EI, human mono- 
cyte/neutrophil elastase inhibitor; IL, interleukin; ECSM, extracapillary 
space medium; SFM, serum-free medium; SDS, sodium dodecyl sulfate; 
PAGE, polyacrylaminde gel electrophoresis; PBS, phosphate-buffered 
saline; HPLC, high-pressure liquid chromatography; TFA, trifluoroacetic 
acid. 
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cells providing soluble factors with stimulatory activity for 
immunocytes has received less attention. 
The objective of this work has been to define the 
biochemical nature of the tumor environment such that the 
soluble molecules which carry stimulatory activity from 
tumor cells to immunocytes become known. We have 
previously characterized a 36 kDa tumor cell-derived pro- 
tein with sequence homologies to lactate dehydrogenase, 
type M which stimulates differentiation of a myeloid pre- 
cursor [2]. We now report the results of a 4-step purifica- 
tion of a T-lymphocyte mitogen from the serum-free 
medium conditioned by an epitheliel cell line. Surpris- 
ingly, the molecule purified to homogeneity is a ca. 45 
kDa protein which, by amino acid composition, amino acid 
sequence analysis of seven tryptic fragments, and immuno- 
reactivity, has been classified as a serpin [6] with signifi- 
cant similarity to human monocyte/neutrophil elastase 
inhibitor. The role of this serpin in tumor immunosurveil- 
lance is discussed in this and the following paper. 
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2. Materials and methods 
2.1. Materials 
Dulbecco's modified Eagle's, Ham's, and AIM-V me- 
dia as well as Hanks' balanced salt solution were pur- 
chased from GIBCO (Grand Island, NY); insulin/transfer- 
rin/sodium selenite medium supplement from Sigma (St. 
Louis, MO); and [3H]thymidine (6.7 Ci/mml; 1 Ci = 37 
GBq) from DuPont-New England Nuclear (Boston, MA). 
Interleukin-2 (IL-2) was obtained as both a purchase from 
Genzyme (Cambridge, MA) and as a gift from Cetus 
(Emeryville, CA). Q-Sepharose Fast Flow resin, Sephacryl 
S-300 (Superfine) resin and a Mono Q (HR 5/5)  chro- 
matography column were bought from Pharmacia LKB 
Biotechnology, (Piscataway, NJ) and a C 4 reverse-phase 
column (4.6 X 250 mm) from Syn Chrom, (Lafayette, IN). 
Precast polyacrylamide (8-16% gradient and 12%) gels 
plus molecular weight standards were obtained from Novex 
(San Diego, CA); silver stain kits, from Integrated Separa- 
tion Systems (Framingham, MA) (Daiichi-II) and ICN 
(Costa Mesa, CA) (Rapid Ag Stain); Aurodye protein stain 
from Amersham (Arlington Heights, IL); a BCA protein 
assay reagent kit in addition to an albumin standard, from 
Pierce Chemicals (Rockford, IL); AccQTag reagents for 
amino acid analysis, from Waters' Associates (Milford, 
MA); and a DIG glycan detection kit, from Boehringer 
Mannheim (Indianapolis, IN). Omegacells-10 and-150 
with 10-kDa molecular weight cut-off filters were bought 
from Filtron (Clinton, MA); Centricon-10 units, from Ami- 
con (Danvers, MA); and Ultrafree-CL Durapore filters, 
from Millipore (Bedford, MA). A Waters HPLC system 
consisting of two 510 pumps and a 990 diode array 
detector was used for purification; the same instrument but 
with a fluorescence detector from MacPherson Instruments 
(Acton, MA) was used for AccQTag analysis. 
The two human T-lymphocyte lines, TILs 618 and 660, 
which were used in the work described in this manuscript 
were established from human melanoma tumors as de- 
scribed previously [I] and the clone of A-431 cells used 
was from Dr. J.E. DeLarco. 
Recombinant human monocyte/neutrophil elastase in- 
hibitor (El) was generated by infection of serum-free Sf9 
insect cell cultures with the El-encoding recombinant virus 
AvNPV-EI; El-containing media were collected 6 days 
later (Sugimora et al., 1994). 
2.2. Methods 
Culturing 
A431 cells were grown continuously for various times 
in a Cellco bioreactor as described previously [1]; one of 
the seven continuous cultures extended to a total of 710 
days. Every 2 days serum-free conditioned medium (about 
50 ml) was collected from the bioreactor for purification. 
Human T-lymphocyte lines (TIL 660 and TIL 618) were 
carried in AIM-V medium supplemented with 1x  10 3 
Cetus U IL-2 per ml. Approximately 48 h preceding the 
commencement of proliferation assays, cells were washed 
twice with and subsequently cultured in serum-free medium 
(SFM). The composition of the latter was a 1: l mixture of 
Dulbecco's modified Eagle's medium (4.5 g of 
glucose/liter) and Ham's F-12 supplemented with insulin, 
transferrin, and sodium selenite at 5 /zg/ml, 5 /zg/ml, 
and 5 ng/ml, respectively. 
Cellular proliferation assays 
The proliferation bioassay indicator cell used was the 
human TIL 660 line whose phenotype as previously re- 
ported [7] is that of virtually pure T-lymphocytes (98% 
CD3 +) with no antigen-presenting cells present. Through- 
out the course of this work, additional TIL lines described 
previously [1,7] were used in parallel with the TIL 660 
line. [3H]Thymidine cellular proliferation assays were per- 
formed in quintuplicate in 96-well fiat-bottomed plates as 
described previously [1]. The final cell concentration was 
6 X 105 cells/ml and to each assay volume of 200/zl/well  
0.5 /zCi of [3H]thymidine (1) was added. 
Biochemical purification 
Steps in the biochemical purification are listed in Table 
1. Briefly, serum-free conditioned medium from A431 
cells grown in the bioreactor was diluted by 10-fold with 5 
mM potassium phosphate buffer (pH 7.5). This diluted 
material was loaded at 4°C onto a Q-Sepharose Fast Flow 
column (4.5 X 17 cm) that had been equilibrated with a 
15-mM potassium phosphate buffer (pH 7.5). The loading 
sample volume ranged between 2 and 4 liters. After com- 
Table 1 
Summary ofpurification 
Stage of Loading Total protein ECs0 Yield of Purification 
purification volume (ml) loaded (mg) (/xg/ml) (mg) protein (mg) (-fold) 
ECSM 200 168 650 - - 
Q-Sepharose 2000 168 125 8.6 7.4 
Sephacryl S-300 5 8.60 33.3 0.740 38.6 
Mono-Q 35 0.740 1.76 0.072 771 
C 4 5 0.072 0.095 0.008 6842 
Protein contents were determined bythe BCA assay for ECSM and AccuTag amino acid analysis for the other samples. 
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pletion of sample loading, the column was washed with 1 
liter of 15 mM phosphate buffer (pH 7.5). This column 
wash was followed by elution with 400 ml of a 15 mM 
phosphate buffer containing 35 mM sodium chloride. A 
linear elution gradient (500 ml total volume) of sodium 
chloride, starting at 35 mM and ending at 200 mM in 15 
mM potassium phosphate buffer (pH 7.5), was then per- 
formed. An additional -liter elution was carried out with 
15 mM phosphate buffer containing 200 mM sodium 
chloride. Fractions of 7.5 ml were collected starting after 
the first one liter isocratic wash, i.e., after the 15 mM 
phosphate buffer (pH 7.5). Bioactivity in the first 200 
fractions was assayed by taking 200/zl aliquots of selected 
fractions (exact fraction numbers are indicated in Fig. 1) 
and diluting them by 7.5-fold with SFM. 
Fractions with bioactivity from the Q-Sepharose chro- 
matography were pooled, concentrated to a volume of ca. 
5 ml using a Filtron stirred cell with a 10-kDa molecular 
weight cutoff membrane, loaded onto an Sephacryl S-300 
column (2.5 X 150 cm) at 4°C, and then eluted with a 
15-mM phosphate buffer (pH 7.5). Each fraction contained 
4.25 ml and bioassays were performed by diluting 200 /xl 
from even-numbered fractions to 1.5 ml, i.e., 7.5-fold, with 
SFM. 
Fractions containing the lymphocyte mitogenic activity 
from the gel filtration chromatography were pooled, con- 
centrated using a Filtron stirred cell with a 10 kDa molecu- 
lar weight cut-off membrane, and re-equilibrated to buffer 
A which contained 25 mM Tris (pH 7.5). This material 
was then loaded onto a Mono Q (HR 5/5)  anion exchange 
column using a Pharmacia/LKB FPLC. After washing the 
column with buffer A to re-establish the baseline, the 
sample was chromatographed at 25°C with a 43-ml salt 
gradient which started with buffer A (3 ml) and ended with 
32% buffer B (buffer A + 0.500 M NaC1) with a flow rate 
of 1 ml/min. Fractions of 1 ml volume were collected and 
bioassays were performed by diluting 100 /~1 from even- 
numbered fractions to 1.5 ml, i.e., 15-fold, with SFM. 
Fractions with the bioactive material from the Mono-Q 
chromatography were pooled, diluted 1:2 with the 
reverse-phase HPLC buffer A (an aqueous olution con- 
taining 0.05% trifluoroacetic acid (TFA) (v/v)), and in- 
jected onto a C 4 reverse-p]hase HPLC column at 25°C. A 
60-min gradient in which buffer B (acetonitrile containing 
0.05% TFA (v/v)) was increased from 0 to 36% in the 
first 30 min and then to 54% by the end of the gradient, 
using a flow rate of 1 ml/min, was then run. Fraction 
volumes of 1 ml were collected and the even-numbered 
fractions were placed in a Speed Vac. Then fraction vol- 
umes were reduced to ca. 200 /zl each, diluted with PBS, 
and assayed for TIL mitogenic activity. 
Protein and amino acid analyses 
Protein concentration of the serum-free conditioned 
medium was determined by the BCA method (Pierce 
Chemicals). The protein content of chromatographic frac- 
tions containing bioactivity was determined by placing 10 
lambda aliquots from pooled fractions at each step of the 
purification in KIMAX glass tubes (3 × 50 mm), the con- 
tents of which were then dried, tubes were evacuated, and 
the samples were hydrolyzed in 6 N HC1 vapor phase with 
a trace of phenol for 20 h at ll0°C. The amino acid 
composition of the purified factor obtained from the re- 
verse-phase HPLC chromatographic fractions was deter- 
mined using the AccuTag amino acid analysis system [8]. 
In order to determine the cysteine content, some samples 
were oxidized with performic acid at 4°C for 3 h and then 
dried down before hydrolysis. For amino acid composition 
analysis, samples were prepared and analyzed in duplicate. 
Carbohydrate detection 
To determine whether the purified material was glyco- 
sylated, 0.8 /~g (mass based on protein content by amino 
acid analysis) of the purified ca. 45 kDa protein was 
electrophoresed using an 8-16% SDS polyacrylamide g l; 
0.1 /~g of transferrin was co-electrophoresed as the posi- 
tive control for the electroblotting step as well as for the 
carbohydrate d tection test. After completion of the PAGE, 
the samples were completely transferred from the gel to 
nitrocellulose by electroblotting. Complete electroblot 
transfer was confirmed by positive Ponceau S (Boehringer 
Mannheim) staining of the transferrin and ca. 45 kDa 
protein bands on the nitrocellulose and the absence of 
detectable protein in the postblotted gel which was devel- 
oped by silver stain. Then, the electroblotted nitrocellulose 
sheet was further analyzed for the presence of oligosachar- 
ride by using the DIG Glycan detection kit. 
Protein sequencing 
To determine the amino-terminal mino acid sequence 
200 pmol of the ca. 45 kDa protein was subjected to 
automated Edman degradation using an Applied Biosys- 
tems model 476A protein sequenator. No signal above 
background, i.e., more than 15 pmol/cycle, was de- 
tectable, which strongly suggested that the amino terminus 
was blocked as well as homogeneity of the purified pro- 
tein. A total of 277 pmol of the purified material was then 
digested with trypsin after reduction and alkylation with 
iodoacetate oobtain fragments for internal sequence deter- 
mination, as described previously (W.M. Keck Foundation 
Biotechnology Resource Laboratory at Yale University, 
New Haven, CT) [2]. These tryptic fragments were chro- 
matographed by HPLC using a C 18 reverse-phase column 
and TFA/H20/acetonitri le buffer system. Seven well-re- 
solved tryptic fragment peaks were then selected for amino 
acid sequence determination. 
Western blot and mobility analyses 
To determine possible similarities between the ca. 45 
kDa protein purified in this work and a recombinant 
human monocyte/neutrophil elastase inhibitor (EI) stan- 
dard, the proteins were first fractionated by SDS/PAGE 
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Fig. 1. Summary of 4 chromatographic steps leading to the purification of the ca. 45 kDa human monocyte/neutrophil elastase inhibitor-like protein. A 
dashed line indicates the optical density at 280 nm for (a-c) and 220 nm for (d); a solid line indicates the bioactivity ([3H]thymidine incorporation), A 
dotted line in the figures shows a gradient (salt gradient for (c) and percent organic phase content for (d)). Pooled fractions with bioactivity for further 
purification were as follows: (a): Q-Sepharose chromatography (68-73); (b): Sephacryl S-300 chromatography (68-73); (c): Mono-Q (FPLC) 
chromatography (19-23); and (d): C 4 reverse-phase (HPLC) chromatography (49-51). 
and then transferred electrophoretically to membranes. For 
a comparison of antigenicity, they were electroblotted onto 
a nitrocellulose membrane and then probed with a rabbit 
antiserum generated against E1 which had been purified to 
homogeneity from U937 cells; this was followed by incu- 
bation with 125I-labeled goat anti-rabbit IgG for visualiza- 
tion [9]. To compare mobility and to assess relative levels 
of purity, the proteins were transferred to a polyvinylidine 
difluoride (PVDF) membrane and then treated with Au- 
rodye protein stain. 
3. Results 
Previously, it was shown that a serum-free supematant 
from an epidermal carcinoma cell line, i.e., the A431 cell 
line, can stimulate the proliferation of human tumor infil- 
trating lymphocytes (TILs) in culture [1]. The finding that 
other cytokines, many of which have been shown to affect 
T-cell signal transduction, e.g., IL-4, IL-6, tumor necrosis 
factor, type alpha (TNF,,), transforming growth factor, type 
beta (TGF~), and leukemia inhibitory factor (LIF), could 
not induce an increase in the rate of [3H]thymidine incor- 
poration into the DNA of these T-cell lines in a culture 
medium devoid of serum or any other proteins except 
insulin and transferrin suggested the presence of an as yet 
uncharacterized T-cell miitogen. In order to identify 
factor(s) with lymphocyte mitogenic activity, a biochemi- 
cal purification was undertaken using the stimulation of 
[3H]thymidine incorporation i to the DNA of TILs as the 
bioassay. Direct correlation between [3H]thymidine incor- 
poration and cell number increase was periodically checked 
to assure the appropriateness of the selected proliferation 
assay. 
Biochemical purification. As indicated by the data pre- 
sented in Table 1 and Fig. 1, a 4-step chromatographic 
procedure which employed open column anion exchange 
chromatography, open column gel filtration chromatog- 
raphy, anion exchange by FPLC, and high-pressure re- 
verse-phase HPLC to purify a protein with T-cell mito- 
genic activity from a serum-free medium conditioned by 
an epidermal carcinoma cell line resulted in a greater than 
6000-fold increase in specific activity. The homogeneity 
and molecular mass of ca. 45 kDa of the purified material 
are shown in the silver-stained gel in Fig. 2. 
Carbohydrate detection. No oligosaccharides were de- 
tectable on the ca. 45 kDa protein band (18 pmol) which 
had been electroblotted onto nitrocellulose, whereas the 
positive control for these experiments which was 100 ng of 
transferrin showed a strong positive signal using the DIG 
glycan detection kit. With a carbohydrate content of ca. 
6% and a molecular weight of 70 kDa, 33.3 pmol of 
monosaccharide moiety was easily detectable on transfer- 
rin. If one N-linked sugar chain with the minimum size of 
five monosaccharides were present in the purified ca. 45 
kDa material, then 90 pmol of monosaccharide moiety 
would be present. Since the staining was unequivocally 
negative, we concluded that this protein was not glyco- 
sylated. 
Protein sequencing. Seven well-resolved tryptic peptide 
fragments of the purified protein were collected from the 
C l8 reverse-phase HPLC peptide map and then subjected 
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Fig. 2. Silver-stained SDS-PAGE (12% gel) analysis of ca. 45 kDa protein purified in this study (fractions 49-51 from C 4 HPLC column) under educing 
conditions. (Identical results were obtained under nonreducing conditions.) 
to amino-terminal mino acid sequence determination. The 
identified sequences obtained are shown in Table 2. Com- 
parison of 6 tryptic fragments with proteins in the Gen- 
Bank database at the National Institutes of Health indi- 
cated identity with sequences 57-69, 97-110, 111-129, 
204-213,  216-244,  and 291-301 of human 
monocyte/neutrophil elastase inhibitor (El), a serine pro- 
tease inhibitor found in monocytes, macrophages, and 
neutrophils, based on its cDNA sequence [10]. 
In a seventh fragment a total of 20 cycles was analyzed; 
amino acids were determined for 19 cycles and they 
matched 19 of the amino acids in sequence 256-275 of El. 
The amino acid present in E1 at position number 18 of this 
tryptic fragment is serine; however, unequivocal amino 
acid assignment could not be made for this position from 
the analysis of the tryptic fragment. 
Thus, the first 6 tryptic fragments correspond exactly to 
97 amino acid residues out of ca. 375 predicted from a 
protein with a molecular weight of ca. 45 kDa, i.e., ca. 
26% of the total residues. When sequences from regions 
common to other serpin family members were aligned and 
the percent of identical amino acids was examined, values 
ranged between 29.7 and 57.9%. Therefore, the sequencing 
results presented here (115 residues), which represent 31% 
of the total sequence of a ca. 45 kDa protein, place the 
protein purified in this study as a member of the serpin 
superfamily of proteins. Furthermore, a strong similarity, if 
not identity, to human monocyte/neutrophil elastase in- 
hibitor (El) is demonstrated. 
Amino acid composition. The amino acid content of the 
ca. 45 kDa protein purified in this work shows a close 
similarity with that of E1 (Table 3). One potentially signifi- 
Table 2 
Amino acid sequence of 7 tryptic fragments 
Tryptic peptide Corresponding hLEI Sequence Number of residues 
residue numbers identical with hLEI 
1 57-69 TFHFNTVEEVHSR 13/13 
2 97 - 110 TYNFLPEFLVSTQK 14/14 
3 I I 1-129 TYGADLASVDFQHASEDAR 29/29 
4 204-213 FAYGYIEDLK 10/10 
5 216-244 VLELPYQGEELSMVILLPDDIEDESTGLK 19/19 
6 256-275 LHEWTKPENLDFIEVNV-LP 19/20 
7 291-301 LGVQDLFNSSK 11 / 11 
The solid bar for the 18th cycle of tryptic fragment 6 indicates an unidentified residue, not a deletion. The indicated amino acid sequence residue numbers 
correspond to the amino acid sequence based on the cDNA directed sequence for human monocyte/neutrophil elastase inhibitor isolated from U937 cells 
[1o]. 
B.Z. Packard et al. / Biochimica et Biophysica Acta 1269 (1995) 41-50 47 
Table 3 
Amino acid composition of the purified ca. 45 kDa protein. The expected 
amino acid residue numbers for the purified ca. 45 kDa protein (middle 
column) determined by amino acid composition analysis were based on a 
total amino acid residue number of 376. The reported amino acid 
composition for the human leukocyte lastase inhibitor determined from 
its cDNA sequence of 379 residues are presented in the right column 
(The tryptophan residue composition was not determined for the ca. 45 
kDa purified protein and, hence, the determined amino acid residue 
number per tool is based on a total of 376.) 
Amino acid #aa/mole  protein hLEI (cDNA) 
from A431 cells 
Asx 43.6 _+ 0.4 41 
Ser 22.2 + 0.4 31 
Glx 52.3 + 1.5 41 
Gly 22.2 _+ 0.8 20 
His 5.6 + 0.4 7 
Arg 12.0+0.8 14 
Thr 18.8 -I- 0.4 22 
Ala 35.0 + 0.4 30 
Pro 11.6+0.4 12 
Cys 4.1 + 0.4 2 
Tyr 9.0+0.8 10 
Val 20.3 + 0.4 18 
Met 10.5+0.8 12 
Lys 36.5 _ 1.2 29 
Ile 18.8+0.1 19 
Leu 41.7 + 1.9 41 
Phe 19.6 + 1.5 27 
Trp ND 3 
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cant difference is in the cysteine content since the ca. 45 
kDa protein purified in this study was determined by 
AccuTag amino acid analysis to contain four cysteines 
after performic oxidation compared with two for El as 
determined from its cDNA sequence [10]. However, the 
experimental error inherent in cysteine residue determina- 
tion is relatively large. Additional significant differences 
were determined for serine (30% less than El) and phenyl- 
alanine (29% less than El), although these residues, partic- 
ularly serine, are susceptible to degradation during hydrol- 
ysis. Except for these three residues, the overall amino 
acid composition determined for these two proteins is 
comparable within experimental error. 
Comparison of ca. 45 kDa protein with recombinant 
human monocyte /neutrophil elastase inhibitor. Fig. 3a 
shows the relative mobility and purity by gold staining of 
the ca. 45 kDa protein described in this study and the 
recombinant El standard. Using a polyvalent antibody, Fig. 
3b indicates the common antigenicity of the two proteins. 
4. Discussion 
The tumor environment can be defined by the molecules 
which are secreted or released specifically at a tumor site 
plus the cells which infiltrate tumorous masses. Indeed, the 
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Fig. 3. Comparison of the mobility, purity, and antigenicity of the ca. 45 
kDa protein with recombinant human monocyte/neutrophil elastase in- 
hibitor (EI), (a) shows that the tumor-derived ca. 45 kDa protein purified 
in the present work (middle lane) co-migrates with recombinant E1 (left 
lane); this gold-stained blot demonstrates the amounts and levels of purity 
of the proteins used for the Western blot. (b) indicates that the two 
proteins stain equivalently with rabbit polyclonal antibody generated 
against E1 isolated from U937. 
48 B.Z Packard et al. / Biochimica et Biophysica Acta 1269 (1995) 41-50 
presence of cells of lymphoid and myeloid origin fre- 
quently found in histologic sections of tumors supports the 
idea of a tumor as an immunoenvironment since it is the 
infiltration into tumorous masses by cells such as lympho- 
cytes, eosinophils, and macrophages that lends credence to 
the existence of a tumor-specific mmune response. Such 
observations formed the basis of the concept of a tumor 
immunosurveillance network as first proposed by Ehrlich 
[ll]. 
Results from many studies have suggested that im- 
munospecificity may be related to the presence of 
molecules displayed exclusively on the plasma membrane 
of tumor cells. Although this molecular recognition mecha- 
nism was believed to be specific, much of the body of data 
that has been collected on various putative tumor antigens 
and receptor complexes suggests that immunospecificity s 
not necessarily due to tumor specfic expression but rather 
to measurable elevated expression levels [12-14]. 
In contrast to the abundance of research in the areas of 
tumor surface markers, very little attention has been fo- 
cused on the molecular identification and characterization 
of the soluble factors with immunomodulatory activity that 
are secreted or released by tumor cells. Potential activities 
of such factors include amplification and recruitment of 
immunocytes leading to infiltration and/or activation of 
immunocytes which may result in eradication of the tumor 
itself. 
The initial objective of this project, which was to 
explore for the possible presence of T-cell mitogens of 
tumor origin, was derived from a general ack of correla- 
tion between in vitro activities of lymphocytes which had 
been grown ex vivo in the presence of the lymphokine 
IL-2 (tumor-infiltrating lymphocytes (TILs)) and their in 
vivo antitumor effectiveness [7,15]. These clinical observa- 
tions suggested that, in addition to the lytic activity that a 
large mass of activated T-cells might bear, a basis for 
antitumor recognition and ultimate tumor eradication might 
lie in the biochemistry of the soluble factors which a tumor 
cell may release in its immediate nvironment. 
Thus, the idea of the possible presence of T-cell mito- 
gens or other immunomodulatory factors of tumor origin 
led to an experiment in which it was shown that four 
irradiated cultured human tumor cell lines could stimulate 
proliferation of several human T-lymphocyte lines [1]. 
Based on biochemical, biophysical, and immunologic as- 
says, this activity was believed to be derived from an 
uncharacterized T-cell mitogen. When a good source of 
this bioactivity was found to be the serum-free supernatant 
from an epidermal carcinoma cell line, a biochemical 
purification was undertaken. 
As data presented in Table 1 and Fig. 1 indicate, four 
consecutive chromatographic steps resulted in the success- 
ful purification to homogeneity of a ca. 45 kDa protein, 
named Oncoimmunin-L, as shown in Fig. 2. The amino 
acid sequence analysis of 7 tryptic fragments obtained 
from this protein showed almost complete identity with 
those found in human monocyte/neutrophil elastase in- 
hibitor [10] (Table 2). The latter had previously been 
purified from the lysate of the human histiocytic lym- 
phoma cell line U937 using the inhibition of pancreatic 
elastase as the assay [16]. The strong immunologic ross- 
reactivity as shown in the Western blot in Fig. 3 where a 
polyclonal antibody generated against the U937-purified 
EI was used as well as an amino acid composition strik- 
ingly similar to recombinant EI (Table 3) further supports 
a significant correspondence b tween Oncoimmunin-L and 
EI. 
Members of the serpin superfamily represent ca. 10% of 
all proteins circulating in human plasma. This group of 
about 40 fairly large (350-400 amino acids) homologous 
proteins, including antithrombin III, c~l-antitrypsin, and 
antichymotrypsin, plays dominant regulatory roles in fibri- 
nolysis, hemostasis, complement activation, and matrix 
proteolysis [17-23]. Additional members of this family [6] 
such as the human proteins squamous cell carcinoma 
antigen (SCCA) [24] plasminogen activator-2 (PAI-2) and 
maspin [25], the avian proteins gene Y and ovalbumin, the 
equine leukocyte lastase inhibitor, and the viral protease 
inhibitor CrmA [26], extend the distribution and range of 
biologic activities associated with this group of proteins to 
include in addition to the expected antiproteinase activity 
clinically significant expression at certain stages of some 
forms of cancer [27-29]. More specifically, the ovalbumin 
serpin family, of which EI is a member, also includes the 
two other proteins which have been associated with cancer, 
i.e., SCCA and maspin [6]. However, no serpin has previ- 
ously been identified to have direct immunomodulatory 
activity such as the lymphocyte mitogenic activity reported 
here. 
Although the family name derives from the function 
most commonly associated with this group of molecules, 
i.e., their central role in controlling the activities of serine 
proteases including critical aspects of blood clotting, their 
compact folded globular structure has permitted evolution 
into multiple conformational states which allow for a 
diversity of function [30,31]. Specifically, it is the structure 
of the sequence variable reactive site loop, a stretch of ca. 
15 amino acids, which has generated most attention in the 
past few years. Here, X-ray crystallographic data have 
defined elements comprising the 4 serpin structural classes, 
i.e., non-inhibitory, cleaved, active, and latent. Moreover, 
recent structural data have clarified mechanisms of activa- 
tion and dysfunction thereof, suggesting future designs for 
therapeutic protease inhibitors [32-34]. 
In addition to protease inhibitory activity, some mem- 
bers of this family of proteins are involved in physiologic 
processes, e.g., tumor suppression, eurotrophism, and heat 
shock, where protease inhibition may not be involved. For 
example, the classic non-inhibitory serpin is ovalbumin, a
molecule in which the conformation of the reactive site 
loop region is a helical stretch of peptide flanked by two 
stalk regions which secure the coil to the body of the 
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protein; this conformation renders the cleavage site loop 
sterically incapable of inhibitory interactions with pro- 
teases [35,36]. Also, in human plasminogen activator in- 
hibitor, type 1 (PAl-l), a latent serpin, the reactive site 
loop becomes unreactive toward serine proteases by as- 
suming a reversible non-inhibitory conformation sponta- 
neously [37]. Thus, since the potential for protease in- 
hibitory activity appears to depend on the conformation of 
the active site loop [38] and this may vary, the findings 
that other types of biologic activities are associated with 
this class of protein are not surprising. Moreover, the 
biochemical mechanism for Oncoimmunin-L's physiologic 
role may indeed be a function of the conformation of its 
reactive site loop. 
The recent discovery by molecular biologic methodol- 
ogy of the tumor suppressor serpin called maspin, for 
which no target protease or ligands have been thus far 
identified, further extends the potential for functional di- 
versity for serpins [25]. Consistent with this expansion of 
physiologic roles is the established ligand-binding, i.e., 
nonproteolytic, properties of the serpins' cortisol-binding 
globulin and thyroxine-binding globulin. 
The biospecificity of the, protein we have characterized 
in this report may be due solely to its localized source of 
synthesis and release. The critical importance of the site of 
release for biologic activity has been demonstrated by 
experiments in which mice bearing tumors have been 
tranfected with genes for cytokines. Specifically, malig- 
nant cells which produced IL-4 as a result of transfection 
with the gene for this cytckine were able to inhibit tumor 
formation in contrast o progressive growth of malignant 
cells at sites of control-trazlsfected c lls [39]. Interestingly, 
eosinophilic and macrophage infiltrates were observed only 
at the site of injection of the cytokine-transfected c lls. In 
another study the metabolic onsequences of TNF~ were 
examined as a function of the site of injection of tumor 
cells transfected with the gene for this cytokine [40]. It was 
shown that, despite similar TNF~ serum levels in animals 
that had received TNF~-secreting tumors intracerebrally or
intramuscularly, cachexia developed only in mice in which 
this cytokine was produced continuously in the central 
nervous system. Thus, the physiologic role a molecule 
plays may depend on the immediate nvironment into 
which it is delivered. 
The release of a tumor-derived factor capable of stimu- 
lating the growth of a class of cells with the potential to 
destroy the tumor itself might appear to be counterproduc- 
tive. However, implicit in the tumor immunosurvelliance 
concept is the existence of a network set up to recognize 
and eradicate cells that have undergone transformation to
states potentially harmful ~to the survival of the organism. 
Thus, a mitogenic signal for a lymphocyte produced by a 
tumor cell may represent another example of participation 
by proteinase inhibitors in immune regulation [41-44]. 
Although similar in function, none of the previously recog- 
nized host-derived antiproteinases with immunomodula- 
tory activity can be classified as members of the serpin 
structural family [22]. 
Additional study on the biochemistry of the tumor 
environment, with focus on tumor-derived soluble factors 
mediating immunomodulatory activities, is necessary to 
fully understand how tumor immunosurveillance operates. 
In addition to the soluble components one would like to 
know the composition and regulation of the cellular con- 
stituents of these putative networks. The present study in 
addition to our previous work [2] addresses one aspect in 
that we have now shown that members from protein 
families not usually directly associated with immunology 
can exhibit immunomodulatory activity if introduced in the 
proper setting. 
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